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The purpose of the study is to develop cephalexin controlled-release matrix tablets by using lower 
proportions of release retardant polymer and to establish their in vitro & in vivo correlation. Tablets were 
compressed by incorporating polymers in a matrix form along with drug which prolong the drug release. 
Twelve formulations were prepared by mixing ethyl cellulose (EC) and hydroxypropyl methylcellulose 
(HPMC) (three different viscosity grades) in various proportions. F-1 to F-4 formulations were prepared 
by incorporating drug, HPMC K4M and ethyl cellulose in 100 : 5 : 5, 100 : 10 : 5, 100 : 15 : 5 and 
100 : 20 : 5; similarly, F-5 to F-8 were prepared with HPMC K15M; and F-9 to F-12 were prepared with 
HPMC K100M using a wet granulation process maintained same proportions, along with drug and EC. 
Tablets were evaluated for their pre-compression and post-compression characteristics and they were 
found to be in limits. From the dissolution testing, F-4 showed 100.34% medicament release in 12 h. 
In vivo studies were conducted on rabbit and pharmacokinetic parameters of the optimized formulation 
were evaluated using HPLC method. It was found that matrix tablets showed increased t1/2 and decreased 
Kel. The design signified that the drug release rate from tablets was influenced by the small proportion 
(around 7% of a tablet weight) of polymer mixture and it controlled 100% medicament release upto 12 h 
effectively with the low grade viscosity of HPMC combination, with good in vitro & in vivo correlation.
Keywords: Matrix tablets. Polymer mixture. Release kinetics. Pharmacokinetics parameters. In vitro 
& in vivo correlation.
INTRODUCTION
In developing countries, people get infected very 
often. Generally, disease causing agents are both gram 
positive and gram negative bacteria, thus proper treatment 
should be taken with medicaments, which have efficient 
action to neutralize the activity of these microorganisms. 
All cephalosporins posses a wide range of bactericidal 
activities. Cephalexin is a first generation cephalosporin, 
and it is an orally active drug. It inhibits cell wall synthesis 
of gram-positive bacteria (Sirisolla, Ramanamurthy, 2015; 
Tripathi, 2013; Reddy, Nagoji, Patnaik, 2015; Reddy, 
Nagoji, Sahoo, 2016). The intension of controlled release 
systems is used to decrease dosage regimen and maintain 
steady-state levels. Thus, it posses better control over acute 
diseases, with maximum utilization of drug by enabling a 
reduction in the total amount of the dose administered and 
leads patient compliance (Chugh et al., 2012). In this work, 
a series of trial has been made to design, formulate and 
evaluate in vitro release of cephalexin matrix to establish 
drug release upto 12 h, as the work was done previously 
for 6 h release matrix tablets (Vijay et al., 2012). The 
formation of the matrix system with the release retardant 
polymer affects the drug release for an extended period 
of time with complete utilization of the drug. The wet 
granulation process is implemented for tablet compression. 
The cephalexin matrix tablets are designed by using EC 
and HPMC (HPMC K4M/HPMC K15M/HPMC 100M) 
in different proportion such as 5 mg: 5 mg, 5 mg: 10 mg, 
5 mg: 15 mg and 5 mg: 20 mg. In all formulations, the EC 
quantity is fixed at 5 mg, and added HPMC grades in a 
range of 5 mg to 20 mg to EC, to prepare polymer mixture. 
Twelve formulations were evaluated for their various 
parameters, i.e., before & after the tablet compression 
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parameters; and pharmacokinetic parameters evaluation of 
the optimized formulation (Gennaro, 2001). The polymer 
mixture is used in a range of 2.85 to 7.14% of the tablet 
weight, which are very low proportions of polymer blend to 
establish the in vitro release of the drug upto 12 h. The effect 
of matrix polymer over evaluated parameters such as drug 
release rate, cumulative% drug released and drug released 
mechanism, and pharmacokinetic parameters were studied 
(Reddy, Nagoji, Sahoo, 2016).
MATERIAL AND METHODS
Cephalexin was gift sample from Ranbaxy Lab, 
Gudgaon, HPMC K4M, HPMC K15M, HPMC K100M, 
EC, Dibasic calcium phosphate, Magnesium stearate and 
Talc used are of analytical grade.
Fourier Transform Infrared (FTIR) spectroscopy
FTIR studies were carried out on pure drug, 
individual polymer and optimized formulation. An equal 
weight of the sample and potassium bromide (about 1 mg 
each) was mixed and compressed to form a pellet and 
scanned in the range of 400 to 4000 cm-1 (Reddy, Nagoji, 
Sahoo, 2016).
Differential Scanning Calorimetry (DSC)
DSC studies were carried out between drug and 
excipients to establish chemical interactions. Basically, 
the thermal attributes of a physical mixture are the sum of 
the thermal properties of individual components (Reddy, 
Nagoji, Sahoo, 2016).
Formulation of controlled release matrix tablets
Required quantities of drug and all excipients were 
passed through the sieve 44 # and then weighed accurately 
and blended properly (except lubricant and glidant) as per 
the formula (in Table I). The wet damp mass was formed 
by slowly adding distilled water q.s (quantity sufficient) 
as granulating liquid. The cohesive material was sieved 
through sieve 12 # to form wet granules. Granules were 
dried at 50 ºC for 2 h in a hot air oven (Universal Hot 
Air Oven) and then passed through 22 # mesh to collect 
uniform size of the granules. Talc and magnesium 
stearate were added to lubricate the granules and then 
compressed them with the help of a single punch-tableting 
machine (Shakti) with tablet hardness maintained in the 
range of 4 to 6.02 kg/cm2 (Rezal, Qadir, Haider, 2003; 
Andreopopulas, Tarantilli, 2001; Parikh, 2005).
Pre-compression evaluation parameters
The ratio of a certain weight of the granules to their 
bulk volume is called as bulk density. Teknik Bulk Density 
Apparatus was used to measure bulk density. Pre-sieved 
granules were placed into a graduated measuring cylinder 
and then the bulk density was calculated by measuring the 
weight and volume (Basak, 2004; Aulton, 2002). It was 
repeated for three times. The ratio of a certain weight of the 
granules to their tapped volume is called as tapped density. 
The granules were filled in a graduate measuring cylinder 
with tap density tester, and operates for a certain number 
of taps until the granules volume reaches a minimum, and 
then the tapped density was calculated. It was repeated for 
three times (Reddy, Nagoji, Patnaik, 2015; Aulton, 2002; 
TABLE I - Composition of tablet formulations
Ingredients F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 F-12
Cephalexin 100 100 100 100 100 100 100 100 100 100 100 100
Ethyl cellulose 5 5 5 5 5 5 5 5 5 5 5 5
*HPMC K4M 5 10 15 20 -- -- -- -- -- -- -- --
*HPMC K15M -- -- -- -- 5 10 15 20 -- -- -- --
*HPMC K100M -- --- -- -- -- -- -- -- 5 10 15 20
DCP** 230 225 220 215 230 225 220 215 230 225 220 215
Talc 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium stearate 5 5 5 5 5 5 5 5 5 5 5 5
Distilled water (in mL) q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Total weight of tablet 
(in mg)
350 350 350 350 350 350 350 350 350 350 350 350
* HPMC is Hydroxypropyl methylcellulose; **DCP is dicalcium phosphate
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Shabaraya, Narayanacharyulu, 2008).
Hausner’s ratio was calculated as the ratio of tapped 
density to bulk density. Carr’s index was calculated as 
the ratio of the difference between tapped density and 
bulk density to the tapped density, multiplied by 100. It 
was repeated for three times (Aulton, 2002; Shirwaikar, 
Jacob, Grover, 2005). Repose angle (θ) can be defined as 
the angle between the surface of a pile of granules and the 
diameter of the cone base; it was calculated by pouring the 
weighed granules into the glass funnel which was firmed 
to a stand at a height of 3 cm. The granules were passed 
through the funnel onto the surface of a graph paper to 
form a cone. Then the height (h) and diameter (d) of the 
cone were measured and the repose angle was calculated. 
Three trials were carried out (Lachman, Lieberman, 2009; 
Cooper, Gunn, 1986). The repose angle can be measured 
using the formula, 
 
Post-compression evaluation for formulated 
matrix tablets
Tension requires to break a compressed tablet 
diametrically is called hardness. The Monsanto hardness 
tester was used to determine the hardness of the tablet. 
Six tablets were used for the hardness measurement 
(Indian Pharmacopoeia, 2010). As per European 
Pharmacopoeia (EP), twenty tablets were randomly 
taken for the calculation of the weight variation test and 
their average weight was determined. Individual tablets 
weights were compared with the average weight (Sirisolla, 
Ramanamurthy, 2015; Lachman, Lieberman, 2009; 
Krishanaiah et al., 2003). Three tablets were randomly 
selected for the measurement of thickness. The tablet 
was placed between two arms of the vernier calipers and 
thickness was measured (Indian Pharmacopoeia, 2010). 10 
tablets were selected randomly and put inside the Roche 
friability test apparatus (Teknik) for the determination 
of friability. Initially 10 tablets were weighed and then 
they were revolved in a drum for four minutes. Then, the 
tablets were dedusted, reweighed and the lost quantity was 
calculated and expressed into percentage value (Indian 
Pharmacopoeia, 2010; Chaudhari, 2005).
Randomly ten tablets were taken, the total weight 
and the average weight were calculated and they were 
grinded individually to fine powder. Powder equivalent 
to 355.6 mg of cephalexin was transferred to a volumetric 
flask (100 mL capacity), added 80 mL of 0.1 N HCl buffer 
to dissolve completely and then made upto 100 mL with 
the buffer solution. Then the whole contents were filtered 
through a Whatman filter paper. Few sample solutions 
were placed in a cuvette and the absorbance were noted 
down using UV-Vis spectrophotometer (Systronic 2203) 
and quantity of the drug in the sample was calculated. 
Similarly, the drug solution prepared in phosphate buffer 
of pH 6.8 and quantity of the drug in the sample was 
calculated (Indian Pharmacopoeia, 2010).
In vitro dissolutions of controlled release tablets 
of cephalexin were studied in USP XXIII dissolution 
apparatus (Electrolab) rotated at 100 rpm. Dissolution was 
carried out in 900 mL of 0.1 N HCl buffer for 2 h, then 
in phosphate buffer of pH 6.8 up to 12 h. The dissolution 
media used for the test was maintained at 37 ºC ± 0.5 ºC 
temperature throughout the experiment and one tablet 
was used in each test. At predetermined time intervals, 
each time 5 mL of samples were pulled out from the 
dissolution medium using a syringe fitted with a pre-filter 
and immediately 5 mL of pure quantity of dissolution 
media was replaced after each withdrawal of samples. The 
absorbance of the withdrawn samples was analyzed at 262 
nm and the drug content was calculated. The dissolution 
studies were carried out for three determinations. The 
cumulative percent drug released was calculated and the 
dissolution graph was plotted by placing time on X-axis 
and cumulative percent drug released on Y-axis (Indian 
Pharmacopoeia, 2010; Raparla, Murthy, 2007).
Zero and first order rate of reaction were calculated 
by incorporating dissolutions data obtained from 12 
formulations. Cumulative amount of drug released to 
time graph, represents zero order release and the equation 
is expressed as, C = K0 t, where K0 is the zero order rate 
constant and t is the time (in h). Log cumulative% of the 
drug remained vs. time graph, represents a first order 
release, and the equation is, Log C = Log C0 - (Kt/2.303), 
where C0 is the concentration of drug at zero time, K is 
the first-order constant and t is the time (Wagner, 1969).
A cumulative% drug released vs. square root of 
time graph, denotes Higuchi model and the equation is, 
Q = K t1/2, where K is the constant expresses the design 
variables of the system and t is the time (in h). The 
equation signifies the drug release rate is inversely depends 
on the square root of time (Higuchi, 1963). Korsmeyer 
Peppas (KP) equation is used to determine the drug release 
mechanism from the dosage form. 12 h dissolutions data 
on drug release were plotted using the KP equation, i.e., 
log cumulative% drug released vs. long time, and then 
exponent ‘n’ was calculated. Mt/M∞ = K tn, where Mt/M∞ 
is the fractional solute release, t is the release time, K is a 
kinetic constant characteristic of the drug/polymer system, 
and ‘n’ is an exponent that characterizes the mechanism 
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of release of tracers. For cylindrical matrix tablets, if the 
exponent n = 0.45, it is Fickian diffusion; if 0.45 < n < 0.89, 
it is non Fickian or anomalous diffusion; and if n=0.89, it 
expresses Case-II Transport or typical Zero order release 
(Korsmeyer et al., 1983).
In vivo analysis was performed by using Cyber lab 
Scientific Instruments liquid chromatography system 
composed of a LC-10AT pump, a SPD-10A UV detector, 
an ODS C-18 column (150 mm x 4.6 mm I.D., 5 μm 
particle size) 25 μL Hamilton injection syringe. Mobile 
phase consisted of a mixture of 2 mM phosphate buffer: 
Acetonitrile: (50:50,%v/v), adjusted to pH 3.5 to 1% 
orthophosphoric acid. The drug was eluted isocratically 
at a mobile phase flow rate of 1.2 mL/min and monitored 
with a UV detector operating at 254 nm. 500 μL of mobile 
phase were used for the preparation of each sample and 
vortexed for 30 sec; and then 20 μL of it was injected into 
the HPLC system. Calibration curve was plotted by using 
a concentration range of 0.025 - 3.2 μg/mL of cephalexin; 
and showed linearity in between the concentration of 
cephalexin and its peak area (R2=0.9990).
The optimized matrix tablets were further 
evaluated for their pharmacokinetic parameters. The 
pharmacokinetic study protocol was approved by the 
IAEC (Reg. No. 1263/bc/16/CPCSEA). Six male adult 
rabbits weighing about 2.5 to 3.5 kg range were selected 
for the study. Food was withdrawn from the rabbits 12 
h before drug administration and until 12 h post dosing, 
but they had free access to water throughout the study. 
The study was conducted as parallel design in which a 
single dose 1.8 mg was administered to rabbits orally. 
The animals were divided into 2 groups containing 3 
animals in each. For one group pure cephalexin was 
given with water and for another group matrix tablet 
was given. At 0.25 h, 0.5 h, 1.0 h, 1.5 h, 2 h, 3 h, 4 h, 
6 h, 8 h and 12h time, blood samples were pulled from 
the marginal ear vein of rabbit; and then the collected 
samples were centrifuged for 10 minutes at 2500-3500 
rpm using Micro centrifuge (Remi Equipment, Mumbai, 
India). Immediately after centrifugation, samples were 
stored in refrigeration condition until the analysis was 
performed. Safety aspects were evaluated by monitoring 
adverse effects and vital symptoms and through physical 
examination.
RESULTS AND DISCUSSION
IR spectrum of the pure drug, polymers and power 
mixtures of the drug, excipients & the polymers were taken. 
The characteristic peaks of cephalexin were obtained at 
3273.31 cm-1, 3056.31 cm-1, 2884.64 cm-1, 1759.14 cm-1, 
1693.56 cm-1, 1396.51 cm-1, 1281.74 cm-1, 1196.87 cm-1, 
1071.49 cm-1, 986.62 cm-1, 818.81 cm-1, 696.33 cm-1 and 
581.56 cm-1 (in Figure 1 to 4). In DSC test, drug peak was 
FIGURE 1 - IR Spectrum of cephalexin alone.
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observed at 199.1 ºC in drug-polymer mixture, whereas for 
the pure drug showed an endothermic peak was obtained 
at 191.34 °C (in Figure 5 and 6). The obtained FT-IR 
spectra indicated good compatibility in between drug and 
excipients. Thermogram peaks indicated there was no phase 
transformation in between the drug and polymers.
FIGURE 2 - IR Spectrum of ethyl cellulose alone.
FIGURE 3 - IR Spectrum of HPMC K4M alone.
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Bulk and tapped densities of the granules of 
twelve formulations were calculated and they ranged 
from 0.365 to 0.394 g/mL and from 0.420 to 0.461 g/mL 
respectively (in Table II). For granules, there were no 
FIGURE 4 - IR Spectrum of cephalexin, with excipients and polymers.
FIGURE 5 - Thermogram of pure drug.
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significant differences in between bulk density and 
tapped density, indicated good granules distribution 
in the compressed matrix tablets. The Hausner’s ratio 
values ranged from 1.114 to 1.197, and the Carr’s index 
values ranged from 12.18 to 14.53%. Hausner’s ratio 
values were less than 1.25 indicating good flow and it was 
observed to be within pharmacopoeia limits. Generally, 
Carr’s index values between 5-15 indicate excellent flow 
property; and the results obtained indicated that the power 
flow properties were within the pharmacopoeias limits. 
Angle of repose values ranged from 23.24 ° to 25.63 ° (in 
Table II). Angle of repose indicated good flow properties 
of granules as its value was less than 25.63 º, and it was 
observed to be within the official standard limits.
The hardness of all the formulations ranged from 
5.52 to 6.02 kg/cm2. The thickness of all the formulations 
FIGURE 6 - Thermogram of drug and polymers.
TABLE II - Precompression parameters of the granules
Formulation 
Code
Bulk Density 
(g/mL) 
Tapped Density 
(g/mL)
Carr’s Index 
(%)
Hausner’s 
ratio ± SD Angle of repose
F-1 0.384 0.441 12.92 1.148±0.03 25.41°
F-2 0.379 0.434 12.67 1.145±0.04 23.24°
F-3 0.394 0.461 14.53 1.170±0.03 24.32°
F-4 0.370 0.422 12.32 1.140±0.04 25.63°
F-5 0.369 0.428 12.18 1.149±0.06 24.21°
F-6 0.365 0.437 14.47 1.197±0.01 24.74°
F-7 0.372 0.428 13.08 1.150±0.03 25.62°
F-8 0.384 0.420 12.28 1.114±0.03 24.37°
F-9 0.370 0.422 12.32 1.140±0.06 23.38°
F-10 0.375 0.421 12.32 1.135±0.01 24.34°
F-11 0.380 0.432 12.23 1.142±0.03 25.12°
F-12 0.371 0.425 13.26 1.190±0.04 25.10°
All values are mean ± standard deviation (SD) for n=3 determination
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was between 2.30 to 2.35 mm. For matrix tablets, the mean 
thickness was almost uniform in all the formulations. 
The weights of the tablets were between 1.71 to 2.30%, 
as the actual weight of the tablet was 350 mg. The 
Pharmacopoeial specification for weight variation limit 
is ± 5% for uncoated tablets weighing more than 324 mg. 
Hence all the formulations were passed the weight 
variation test.
Friability of all the formulations was determined, and 
the values were in the range from 0.32 to 0.82%. Percent 
drug content of cephalexin was within 98.48 to 99.30% 
for all the twelve formulations (in Table III). Friability of 
the formulated tablets was found to be below 1%, which 
indicated good mechanical resistance of the tablets. Hence 
all the formulations were within the Pharmacopoeial 
limits. Based on the obtained results, percent drug content 
of the drug in all the formulated tablets was found to be 
within limit, and indicated uniformity of mixing.
Results obtained in the in vitro drug release study 
of different formulations are shown in Table IV. The data 
indicated that formulations from F-1 to F-12, released 
92.34%, 93.89%, 94.36%, 100.34%, 89.91%, 90.6%, 
91.63%, 92.5%, 92.48%, 95.41%, 95.48% and 97.47% of 
the drug respectively at the end of 12 h. Based on obtained 
in vitro drug release dissolution data, it was observed 
that, the% of drug release gradually increased from F-1 
to F-4 i.e., 92.34%, 93.89%, 94.36%, and 100.34%, 
respectively, from F-5 to F-8 i.e., 89.91%, 90.6%, 
91.63%, and 92.5%, respectively, and from F-9 to F-12 
i.e., 92.48%, 95.41%, 95.48% and 97.47% respectively, 
at the end of 12 h. From the in vitro release data profile, it 
TABLE III - Evaluation parameters of the compressed tablets
Formulation 
Code
Thickness 
(mm) ± SD
Weight variation 
(%)
Hardness 
(kg/cm2) ± SD
Friability 
(%) ± SD
Drug Content 
(%) ± SD
F-1 2.30±0.35 1.93 5.22±0.01 0.32±0.01 99.25±0.40
F-2 2.32±0.45 1.82 5.72±0.36 0.76±0.01 99.13±0.25
F-3 2.35±0.37 1.71 6.02±0.01 0.82±0.01 99.15±0.16
F-4 2.30±0.39 1.85 5.53±0.36 0.66±0.01 99.30±0.41
F-5 2.35±0.44 2.19 5.55±0.35 0.42±0.01 98.48±0.41
F-6 2.33±0.43 1.83 5.76±0.36 0.49±0.01 99.10±0.49
F-7 2.35±0.38 2.30 5.88±0.33 0.61±0.01 98.58±0.52
F-8 2.32±0.29 1.98 5.55±0.32 0.45±0.01 99.30±0.44
F-9 2.31±0.55 1.76 5.52±0.36 0.59±0.01 98.64±0.06
F-10 2.35±0.52 1.86 5.78±0.33 0.60±0.01 98.56±0.56
F-11 2.32±0.56 2.10 5.58±0.32 0.49±0.01 98.81±0.58
F-12 2.31±0.33 1.94 5.54±0.36 0.55±0.01 99.11±0.44
All values are mean ± standard deviation (SD) for n=3 determination
was observed that when individual HPMC grade polymer 
concentration increases in the formulations, it increases% 
drug release from the dosage form, i.e., F-1 < F-2 < F-3 
< F-4 (K4M used formulations), F-5 < F-6 < F-7 < F-8 
(K15M used formulations), and F-9 < F-10 < F-11 < F-12 
(K100M used formulations). Based on% of drug release, 
F-1, F-2, F-3, F-5, F-6, F-7, F-8, F-9, F-10 and F-11 
formulations could not able to release more than 90% 
and 95.48% of the drug at 10 h and 12 h respectively i.e., 
they hardly released approximately 5.48% drug in last 
two hours in comparison to F-4 and F-12 formulations, 
which was not complied to the intended study design; 
and it was found that their polymer combination were 
not in appropriate ratio to control the drug release, where 
as formulations F-4 and F-12 were released the drug in 
controlled and efficient manner upto 12 h, and their% 
released were 100.34 and 97.47 respectively. From 
the data obtained from different formulations, it was 
concluded that the formulation F-4 (EC: HPMC K4M 
in 5 mg: 20 mg ratio) released 100.34% of cephalexin 
in 12 h could be optimized as the best formulation as it 
prevailed 100% release of the drug. 
Data of in vitro release were fitted to different 
equation and kinetic models to explain the release kinetics 
of cephalexin from the controlled release matrix tablet. 
Estimated data were plotted according to the zero order 
equation and first order equation, the formulations showed 
with regression values between 0.9548 and 0.9899 in zero-
order, & 0.9460 and 0.9747 in first order (in Table V). 
From the data obtained from different formulations, 
zero order release rate constant showed fairly linearity 
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TABLE IV - In vitro dissolution profile for formulations F-1 To F-12 (± SD)
Time (h) F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 F-12
1 18.66 ±0.19
16.08 
±0.15
21.11 
±0.14
15.48 
±0.16
25.11 
±0.15
26.7 
±0.21
25.24 
±0.13
21.03 
±0.13
18.59 
±0.12
20.25 
±0.19
20.60 
±0.16
15.09 
±0.13
2 29.33 ±0.12
26.19 
±0.19
27.18 
±0.18
25.33 
±0.24
28.21 
±0.26
28.9 
±0.16
28.47 
±0.16
26.75 
±0.18
24.55 
±0.15
24.34 
±0.12
26.10 
±0.13
23.48 
±0.15
3 56.02 ±0.26
43.25 
±0.22
45.55 
±0.15
39.05 
±0.16
49.65 
±0.21
49.61 
±0.12
50.78 
±0.12
52.74 
±0.15
50.21 
±0.19
50.44 
±0.13
50.24 
±0.18
50.84 
±0.13
4 57.48 
±0.18
54.63 
±0.20
53.29 
±0.12
40.26 
±0.18
51.98 
±0.12
55.01 
±0.18
56.06 
±0.18
57.84 
±0.12
55.40 
±0.12
55.79 
±0.18
56.19 
±0.15
55.68 
±0.12
5 59.37 ±0.20
60.46 
±0.25
60.73 
±0.16
56.89 
±0.12
57.23 
±0.18
57.19 
±0.16
59.47 
±0.14
60.73 
±0.20
58.94 
±0.16
60.84 
±0.14
60.35 
±0.14
60.78 
±0.14
6 60.54 ±0.23
64.4 
±0.22
69.33 
±0.13
65.84 
±0.13
60.00 
±0.15
59.53 
±0.13
59.89 
±0.16
66.30 
±0.15
60.13 
±0.13
63.57 
±0.26
63.71 
±0.25
65.42 
±0.13
7 65.79 ±0.21
69.8 
±0.18
75.17 
±0.13
73.96 
±0.13
60.59 
±0.14
63.05 
±0.18
54.16 
±0.21
67.22 
±0.16
63.82 
±0.24
69.46 
±0.16
69.58 
±0.20
70.96 
±0.18
8
69.44 
±0.20
72.57 
±0.21
75.46 
±0.18
79.16 
±0.17
65.26 
±0.19
67.99 
±0.12
69.88 
±0.15
69.87 
±0.13
67.39 
±0.19
73.45 
±0.13
76.15 
±0.26
78.49 
±0.14
9 71.92 
±0.18
74.61 
±0.12
77.65 
±0.26
82.95 
±0.12
70.22 
±0.22
71.63 
±0.23
79.37 
±0.13
71.93 
±0.12
73.68 
±0.14
78.35 
±0.17
85.13 
±0.19
88.26 
±0.12
10 78.19 ±0.24
79.27 
±0.21
79.98 
±0.18
91.65 
±0.21
73.28 
±0.13
78.78 
±0.16
85.06 
±0.17
77.53 
±0.24
75.87 
±0.25
82.89 
±0.15
88.29 
±0.24
92.84 
±0.14
11 86.07 ±0.21
85.42 
±0.16
88.48 
±0.17
96.47 
±0.16
83.78 
±0.12
84.47 
±0.13
87.25 
±0.20
88.86 
±0.26
80.99 
±0.16
88.43 
±0.13
92.66 
±0.22
94.26 
±0.16
12 92.34 
±0.18
93.89 
±0.18
94.36 
±0.15
100.34 
±0.14
89.91 
±0.13
90.60 
±0.18
91.63 
±0.12
92.50 
±0.20
92.48 
±0.13
95.41 
±0.13
95.48 
±0.20
97.47 
±0.13
All values are mean ± standard deviation (SD) for n=3 determination
TABLE V - Release kinetics of formulated matrix tablets
Formulation Code
Correlation Coefficient Zero Order Release Rate 
constant, K0 (h-1)Zero order First order
F-1 0.9548 0.9524 6.0380
F-2 0.9670 0.9627 6.8202
F-3 0.9693 0.9683 6.6801
F-4 0.9899 0.9545 8.0433
F-5 0.9730 0.9535 5.5833
F-6 0.9784 0.9641 5.6471
F-7 0.9688 0.9613 6.0809
F-8 0.9559 0.9538 6.2138
F-9 0.9596 0.9460 6.1734
F-10 0.9701 0.9569 6.7321
F-11 0.9763 0.9747 7.0603
F-12 0.9711 0.9679 7.7538
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with K0 values between 8.0433 and 5.5833. The in vitro 
release profiles of drug from all the formulations could 
be better expressed by Higuchi’s equation, as the plots 
showed high linearity with R2 values between 0.9753 and 
0.9914. It indicates that diffusion mechanism involved 
in the release of the drug from the tablets. To confirm the 
diffusion mechanism, the data were fit into Korsmeyer 
Peppas equation. From the slope ‘n’ values are found 
ranging from 0.4655 to 0.7473 (Table VI). Data obtained 
from all necessary parameters, it was concluded that 
the formulation F-4 (EC: HPMC K4M in 5 mg: 20 mg 
ratio) released 100.34% of cephalexin in 12 h could be 
optimized as the best formulation as it prevailed cent 
percentage release of the drug. As per release mechanism 
studies, the drug release pattern followed non-fickian 
diffusion.
Required pharmacokinetic parameters were 
estimated as shown in the Table VII. A graph was plotted 
to establish correlation in between in vitro zero order 
dissolution rate constant (K0) and in vivo maximum 
serum concentration (Cmax), of the pure and the optimized 
formulation of cephalexin and the value was 0.9950 
(in Figure 7). The elimination rate constants (Kel) of 
matrix tablets and the pure drug were 0.2289 h-1 and 
0.693 h-1 respectively. The elimination half life (t 1/2) of 
the matrix tablets and the pure drug were 3.027 h and 
1 h respectively. The tmax values for the pure drug and 
matrix tablets were 1 h and 8 h respectively. From the 
in vivo pharmacokinetic studies, three time reduction 
in elimination rate indicating a slow elimination of the 
drug from the body. Based on the elimination half life 
(t1/2) of the matrix tablets and the pure drug, it indicated 
slow elimination and long residence time of the drug 
in the body. Moreover, AUMC of optimized tablet was 
increased more than twofold in comparison to pure drug. 
The absorption rate constant Ka of matrix tablets was 
slower than the pure drug, indicated a slower absorption 
of the drug. In spite of that, there was no significant 
change in Cmax of the pure drug and matrix tablets. 
Significant changes in Kel, t1/2, Ka, tmax and AUMC values 
of the drug when administered as matrix tablets clearly 
indicated that the matrix tablets developed in the study 
showed a controlled release of the drug confirming the 
results of in vitro studies with their correlation coefficient 
value 0.9950. A good correlation was observed between 
in vitro and in vivo parameters.
CONCLUSION
Cephalexin controlled-release matrix tablets were 
successfully designed using hydrophilic and hydrophobic 
polymer. There were no incompatibility interactions 
TABLE VI - Diffusion characteristics of formulated matrix tablets
Formulation 
code
Kinetic models
Higuchi Peppas model
R2 R2 n
F-1 0.9774 0.9768 0.5633
F-2 0.9914 0.9906 0.7074
F-3 0.9893 0.9843 0.5939
F-4 0.9943 0.9968 0.7473
F-5 0.9834 0.9823 0.4879
F-6 0.9860 0.9784 0.4655
F-7 0.9753 0.9752 0.5053
F-8 0.9795 0.9802 0.5781
F-9 0.9797 0.9749 0.5955
F-10 0.9878 0.9800 0.6105
F-11 0.9909 0.9842 0.6162
F-12 0.9890 0.9811 0.7382
TABLE VII - Pharmacokinetic parameters of cephalexin
Parameters Pure cephalexin Matrix tablets
Kel (h-1) 0.6930 0.2289
T1/2 (h) 1 3.027
Ka (h-1) 3.580 0.3784
Tmax (h) 1 8
Cmax (µg/mL) 1.5670 1.3440
AUMC (µg h/mL) 49.1160 127.354
FIGURE 7- Correlation between in vitro zero order dissolution 
rate constant (K0) and in vivo maximum serum concentration 
(Cmax) of the pure and optimized controlled release formulation 
of cephalexin.
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in between polymers and drug. Results from in vivo 
pharmacokinetic parameters confirmed the drug release 
from the cephalexin matrix tablets in a controlled 
manner with longer residence time and having effective 
pharmacological action. There was good in vitro and in 
vivo correlations as per obtained datas. It can also be 
concluded that mixture of lower viscosity grade, i.e., 
HPMC K4M with EC (mixture about 7% of a tablet 
weight) in matrix form, extended the drug release from 
the dosage form upto 12 h completely thereby increasing 
patient compliance and reduces the adverse effects.
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